Alternative Data for TG Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 12 | Sign up | Sign up | Sign up |
| Sentiment | 95 | Sign up | Sign up | Sign up |
| Webpage traffic | 46,000 | Sign up | Sign up | Sign up |
| Employee Rating | 44 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 249 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 21,433 | Sign up | Sign up | Sign up |
| X Followers | 3,198 | Sign up | Sign up | Sign up |
| X Mentions | 125 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 18 | Sign up | Sign up | Sign up |
| Linkedin Employees | 497 | Sign up | Sign up | Sign up |
About TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases.
| Price | $27.96 |
| Target Price | Sign up |
| Volume | 1,654,585 |
| Market Cap | $4.46B |
| Year Range | $26.39 - $39.19 |
| Dividend Yield | 0% |
| PE Ratio | 10.09 |
| Analyst Rating | 83% buy |
| Industry | Biotechnology |
In the news
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX)March 10 - Yahoo Entertainment |
|
Bank of America Securities Bearish on TG Therapeutics (TGTX) Post EarningsMarch 8 - Yahoo Entertainment |
|
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual MeetingMarch 6 - GlobeNewswire |
|
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business UpdateFebruary 23 - GlobeNewswire |
|
TG Therapeutics Publishes Five-Year Study On BRIUMVI MS TreatmentFebruary 16 - Benzinga |
|
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple SclerosisFebruary 8 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 162M | 28M | 134M | 391M | 33M | 2.430 |
| Q2 '25 | 141M | 19M | 122M | 28M | 38M | 0.170 |
| Q1 '25 | 121M | 16M | 105M | 5.1M | 12M | 0.030 |
| Q4 '24 | 108M | 15M | 93M | 23M | 33M | 0.150 |
| Q3 '24 | 84M | 9.3M | 75M | 3.9M | 15M | 0.020 |
Insider Transactions View All
| Echelard Yann filed to sell 223,816 shares at $32.6. November 25 '25 |
| Lonial Sagar filed to sell 94,061 shares at $32.2. September 12 '25 |
| Echelard Yann filed to sell 228,816 shares at $36.9. June 16 '25 |
| Power Sean A filed to sell 660,611 shares at $28.5. January 7 '25 |
| Power Sean A filed to sell 670,632 shares at $30.3. January 7 '25 |
Similar companies
Read more about TG Therapeutics (TGTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - TG Therapeutics
The Market Cap of TG Therapeutics is $4.46B.
As of today, TG Therapeutics' PE (Price to Earnings) ratio is 10.09.
Currently, the price of one share of TG Therapeutics stock is $27.96.
The TGTX stock price chart above provides a comprehensive visual representation of TG Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling TG Therapeutics shares. Our platform offers an up-to-date TGTX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, TG Therapeutics (TGTX) does not offer dividends to its shareholders. Investors interested in TG Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of TG Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
